(Q71847701)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7601942%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

title

Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7601942%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference

D. G. Durham-Pierre

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7601942

7 June 2024

C. S. Walters

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7601942

7 June 2024

R. M. Halder

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7601942

7 June 2024

H. N. Pham

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7601942

7 June 2024

E. A. Vanderpool

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7601942

7 June 2024

language of work or name

English

0 references

publication date

1 July 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7601942%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

21 October 2019

https://api.elsevier.com/content/article/PII:0190962295900055?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

https://api.elsevier.com/content/article/PII:0190962295900055?httpAccept=text/plain

7 June 2024

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Journal of the American Academy of Dermatology

7 June 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7601942%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7601942%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7601942%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

26-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7601942%20AND%20SRC:MED&resulttype=core&format=json

New observations on vitiligo and ocular disease

21 October 2019

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Ocular disturbances in vitiligo

7 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Audiologic abnormalities in cases of vitiligo.

7 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Antibodies to normal human melanocytes in vitiligo

7 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Detection of Antibodies to Melanocytes in Vitiligo by Specific Immunoprecipitation

7 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

The significance of vitiligo antibodies.

7 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Correlation between vitiligo antibodies and extent of depigmentation in vitiligo

7 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Relation Between the Incidence and Level of Pigment Cell Antibodies and Disease Activity in Vitiligo

7 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

T and B lymphocytes in vitiligo

7 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

T cell profiles in vitiligo

7 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study

7 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives

7 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Natural cell-mediated cytotoxicity in vitiligo

7 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Circadian rhythm of natural killer cell activity in vitiligo

7 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

T cell subpopulations in vitiligo: a chronobiologic study

7 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Plasma α-melanocyte-stimulating hormone, β-endorphin, met-enkephalin, and natural killer cell activity in vitiligo

7 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity

7 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Lymphokine-activated killer cells. Analysis of progenitors and effectors

7 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Regulation of tyrosinase in human melanocytes grown in culture

7 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin

7 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Lymphotoxin enhances the susceptibility of neoplastic and preneoplastic cells to natural killer cell mediated destruction.

7 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

7 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/0190-9622(95)90005-5

7 June 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7601942%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference